Innovation at Farmalider

At Farmalider, we believe that ideas are the driving force behind progress. True innovation arises when a brilliant vision is transformed into real solutions that improve people’s health and quality of life.


As a pioneering strategic partner in pharmaceutical innovation, we offer an end-to-end service that covers every stage of the value chain — from idea generation, research, and development to intellectual property protection, licensing, manufacturing, and supply.
Our global approach makes us a trusted reference capable of anticipating needs, delivering differentiated solutions, and creating sustainable value in the industry.

Intellectual Property: A Solid Strategy Driving Innovation

Innovation at Farmalider is supported by a robust industrial protection strategy that ensures the safety and competitiveness of our developments on an international scale:

Extensive patent portfolio

18 patent families and 333 patent registrations worldwide, reflecting our firm commitment to innovation

International coverage

Protection in 58 countries, with planned expansion into new strategic markets

Proven success

294 granted patents and no rejections — evidence of strong, recognized know-how

Differential therapeutic focus

Innovative formulations such as the combination of ibuprofen and tramadol, alongside advanced controlled-release technologies

This comprehensive model enables us to effectively protect our assets, strengthen our leadership in innovation, and remain at the forefront of a highly competitive and regulated sector.

Products in Phase III Clinical Trials

Farmalider currently has three patented products in ongoing Phase III clinical trials, reflecting our strong commitment to therapeutic innovation and to finding differentiated solutions in areas of high unmet medical need.

1. Innovative Combination Therapy for Moderate to Severe Pain

Fixed-dose combination of ibuprofen (arginine/arginate) 400 mg and tramadol HCl 37.5 mg, available in two formulations:

  • IV infusion solution → hospital use (visceral pain)
  • Oral granules for solution → outpatient and home use (somatic pain)

 

Therapeutic indication: treatment of moderate to severe pain in adults, particularly postoperative pain.

 

Differential value:

  • Combines a reference NSAID with a subtherapeutic dose of an opioid, achieving effective analgesia with an improved safety profile.
  • Promotes multimodal analgesia (as recommended by the WHO), acting through complementary mechanisms (peripheral and central).
  • Reduces the need for high-dose opioids, aligning with the global priority of minimizing opioid use and adverse effects.
  • Patent granted and under extension for new indications.


Participating centers in Spain:

  • Hospital Clínico San Carlos
  • Hospital Universitario de Móstoles
  • Hospital Universitario Infanta Cristina,
  • Hospital Central de la Cruz Roja
  • Hospital Gregorio Marañón
  • Hospital de La Princesa
  • Hospital Puerta de Hierro Majadahonda
  • Hospital La Paz (Madrid)
  • Hospital HM Puerta del Sur (Madrid)
  • Hospital Universitario La Luz (Madrid)

2. Patented Treatment for Erosive Hand Osteoarthritis

Farmalider has developed a patented oral treatment for erosive hand osteoarthritis — a painful and disabling condition that affects quality of life and for which there are currently no effective medications available.

Therapeutic indication: treatment of erosive hand osteoarthritis.

Differential value:

  • Expected to be the first and only therapeutic option capable of addressing both the signs and symptoms of this disease.
  • Simple once-daily oral formulation that improves tolerability and adherence.
  • Active international patent protecting this innovation.

 

A dose-finding Phase II study was completed with a well-known marketed drug, focused on severe pain as the primary endpoint. A multicenter clinical trial is currently ongoing in Spain, Italy, and Portugal.

Farmalider

Commitment to innovation

Through these Phase III developments, Farmalider reinforces its leadership in applied research, protecting its advances through a solid intellectual property strategy and moving forward toward solutions that improve patients’ quality of life in areas of high prevalence and unmet medical need.

At Farmalider, innovation is at the heart of everything we do.
Because by inspiring every day, together we drive a better future.